Riverside Treatment Services Lansdowne

Riverside Treatment Services Lansdowne is an addiction-treatment facility located in Rosedale, MD. The facility's programming is outpatient (Outpatient, MAT), not residential. What follows is an orientation — not a review — to the practical questions worth asking before admission.

Care levels at Riverside Treatment Services Lansdowne

The care-level question matters because what a facility offers is what it can realistically treat well. Riverside Treatment Services Lansdowne is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Before admission, an independent clinical assessment (from a primary-care doctor, licensed substance-use counselor, or addiction-medicine physician) can confirm whether Riverside Treatment Services Lansdowne's offerings match the clinical need.

Insurance and payment

Riverside Treatment Services Lansdowne accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The single most useful pre-admission move on insurance is requesting the facility send you — in writing, by email — the specific benefits verification for your specific plan product. That document is the answer to most post-admission billing disputes.

Specialty programming

The facility's documented specialty programming includes: Young adults, Adult women, Pregnant/postpartum women. If that matches what you or your family member need, great — and worth asking specifically about what the programming looks like day-to-day (how many hours per week of specialty-specific content, who leads it, what credentials they hold).

Before you call

Three questions to put to Riverside Treatment Services Lansdowne before admission: the specific ASAM level the facility is billing; the written Verification of Benefits for your specific plan product; the MAT policy (continuation of buprenorphine or methadone during residential, specifically). The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation. Getting answers in writing protects against the downstream surprises.